Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese (Q81073738)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 July 2005

Language	Label	Description	Also known as
English	Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese	scientific article published on 01 July 2005

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16105759%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16105759%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

based on heuristic

inferred from title

myelodysplastic syndrome

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

author name string

J M Li

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16105759%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Y Shen

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16105759%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

D P Wu

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16105759%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

H Liang

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16105759%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

J Jin

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16105759%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

F Y Chen

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16105759%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Y P Song

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16105759%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

E Y P Song

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16105759%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

X F Qiu

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16105759%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

M Hou

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16105759%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Z C Qiu

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16105759%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Z X Shen

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16105759%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

1 July 2005

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16105759%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

International Journal of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16105759%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

82

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16105759%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16105759%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

48-54

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16105759%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

https://scigraph.springernature.com/pub.10.1532/ijh97.a10424

0 references

Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16105759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: single-center experience.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16105759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16105759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Comparison of low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor to intermediate-dose cytosine arabinoside and mitoxantrone with or without etoposide in the treatment of relapsed acute myeloid le

1 reference

https://pubmed.ncbi.nlm.nih.gov/16105759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute myeloid leukemia in adults

1 reference

https://pubmed.ncbi.nlm.nih.gov/16105759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hematopoietic stem cell transplantation in the new millennium: report from City of Hope National Medical Center.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16105759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapy-related acute promyelocytic leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16105759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/16105759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16105759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).

1 reference

https://pubmed.ncbi.nlm.nih.gov/16105759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute leukemia following a previous malignancy: do acute lymphoid leukemia and acute myeloid leukemia have common risk factors?

1 reference

https://pubmed.ncbi.nlm.nih.gov/16105759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A study of the haematologic spectrum of myelodysplastic syndrome.

1 reference

https://pubmed.ncbi.nlm.nih.gov/16105759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Myelodysplastic syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/16105759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

1 reference

https://pubmed.ncbi.nlm.nih.gov/16105759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/16105759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/16105759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors

1 reference

https://pubmed.ncbi.nlm.nih.gov/16105759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/16105759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/16105759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/16105759

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q81073738&oldid=2205346752"